Business Wire
Welcome
  • Log In
  • Sign Up
Search News:
Help
 ViroStatics srl
December 09, 2008 04:00 AM Eastern Daylight Time 

ViroStatics’ President and CEO, Dr. Franco Lori, to address HIV DART 2008 in Puerto Rico

SASSARI, Italy & PRINCETON, N.J.--(BUSINESS WIRE)--ViroStatics, srl today announced the Company’s President and CEO, Dr. Franco Lori, will be speaking at the HIV DART 2008 conference in Puerto Rico on Wednesday, December 10th. Dr. Lori’s presentation, “Development of VS411, a Virostatic Drug Fixed Dose Combination (FDC) Designed to Inhibit Both HIV and Immune Hyperactivation,” will highlight the final results from the Company’s Phase I study of its lead product for the treatment of HIV disease, VS411. In addition, Dr. Lori will discuss the Company’s Phase II development program for VS411 as well as recent advancements in ViroStatics’ drug discovery program.

“Development of VS411, a Virostatic Drug Fixed Dose Combination (FDC) Designed to Inhibit Both HIV and Immune Hyperactivation”

About HIV DART 2008

The focus of this influential meeting is to assemble clinicians, researchers and basic scientists together to advance knowledge of the ongoing drug development processes in antiretroviral research. HIV DART 2008 uniquely blends the areas of biology, chemistry, pharmacology and clinical research to provide the scientific community with an increased understanding of the current and future challenges in therapeutics for HIV infection.

About Virostatics

ViroStatics srl, an Italian pharmaceutical company with operations in Sassari and Pavia, Italy and Princeton, NJ, USA is committed to discovering and developing novel combination therapeutics to address significant medical needs in HIV/AIDS, chronic infections and related fields. The company is developing its lead product, VS411, as the first fixed-dose combination of two drugs that not only decrease HIV replication but also protect and conserve the immune system. VS411 has completed Phase I and is now undergoing evaluation in a multinational Phase II development program. ViroStatics has also developed novel biomarker assays and a proprietary screening methodology to rapidly and efficiently identify cytostatic agents with potential to inhibit viral replication and control the over-stimulation of the immune system that is believed to drive the progression of HIV to AIDS. ViroStatics is committed to expanding its pipeline and product portfolio by in-licensing early- and late-stage compounds and exploring co-development opportunities that fit the Company's expertise in specialty pharmaceuticals and biopharmaceuticals.

Contacts

ViroStatics srl
Michael Stevens, PharmD, 609-987-2305
Chief Development Officer
m.stevens@virostatics.com
www.virostatics.com

 ViroStatics srl

Company Information Center

ViroStatics srl RSS feed for ViroStatics srl

Share

  • Facebook
  • Twitter
  • LinkedIn
  • Delicious
  • Reddit
  • StumbleUpon
  • Digg
  • MySpace
  • Newsvine
  • Google Bookmark
  • Yahoo! Bookmark
  • EmailEmail
Tweet
  • EmailEmail
All News
Business Wire
  • Home
    • Home
    • Membership Benefits
    • Submit a Press Release
  • News
    • All News
    • News with Multimedia
    • News by Industry
    • News by Subject
    • News by Language
    • RSS Feeds
    • Business Wire Mobile
    • Features
    • Company NewsCenters
    • Annual Reports
  • Events
    • Trade Shows & Events
    • Earnings & Conference Calls
    • Business Wire Events
  • PR Services
    • Press Release Distribution
    • Distribution Lists
    • Industry Targeting
    • LatinoWire & Ethnic Media
    • Public Policy Wire
    • Trade Show Services
    • Photos & Multimedia Marketing
    • GloMoSoMe
    • Measurement & Analytics
    • Monitoring
    • Fax & Email Services
    • Online Newsrooms
    • News Feeds
  • IR Services
    • Material News Disclosure
    • XBRL
    • EDGAR (US)
    • IPO Services
    • SEDAR (Canada)
    • European Disclosure
    • Corporate Social Responsibility (CSR)
    • Investor Targeting
    • Mobile Alerts
    • Fax & Email Services
    • IR Sites
    • IR Resource Center
  • SEO Services
    • Press Release Optimization
    • EON: Enhanced Online News
    • Webinars & Resources
  • Journalist Tools
    • PressPass: Your News
    • Conduct Surveys
    • Business Wire News Feeds
    • Business Wire News On Your Website
    • Journalism Associations
  • Support & Education
    • FAQ
    • How to Write a Press Release
    • How To Optimize a Press Release for Search
    • Find Your News Online
    • Sample Press Release
    • Features News Tips
    • International Media Tips
    • SEC Regulations
    • Exchange Guidelines
    • White Papers
    • Webinars & Podcasts
    • Get WiredIn!
  • About Us
    • Business Wire Newsroom
    • Contact Us
    • History
    • Jobs
  • About Us
  • Contact Us
  • Site Map
  • Privacy Statement
  • Terms of Use
  • ©2013 Business Wire

More Business Wire sites

  • Canada
  • UK/Ireland
  • Deutschland
  • France
  • Italy
  • Japan
  • EON: Enhanced Online News
  • Tradeshownews.com
  • PYMNTS.com

About Us

  • Business Wire Newsroom
  • Contact Us
  • Business Wired blog

News on BusinessWire.com

  • All News
  • RSS Feeds
  • Business Wire Mobile Apps

Follow Us on Twitter

  • @BusinessWire
  • @BWSportsWire
  • @BWPolitics
  • @BWCSRNews
  • @EONpr
  • @TradeshowNews
  • @BW_Canada
  • @BWIntlMedia
  • @BWInfoDiva
  • @BusinessWireFR
  • @BWLatinoWire

Like Us on Facebook

  • Business Wire
  • Tradeshow News